Data and Expert Considerations Supporting Cilta-cel as Second-Line Treatment for Robert

EP: 1.Meet Sarah, a 55-year-old Businesswoman With Multiple Myeloma Considering CAR-T Therapy With Ide-cel

EP: 2.Clinical Decision Making in Multiple Myeloma: CAR-T in the 2nd Line Treatment Setting

EP: 3.Ide-cel vs. Cilta-cel: Tailoring CAR T in Myeloma

EP: 4.Sarah’s Journey Through CAR-T Therapy: Pre-, Peri-, and Post-Treatment Considerations with Ide-cel

EP: 5.Getting to Know Robert, a 72-Year-Old Retired Teacher Facing a Myeloma Relapse and Considering CAR-T Therapy with Cilta-cel

Now Viewing

EP: 6.Data and Expert Considerations Supporting Cilta-cel as Second-Line Treatment for Robert

EP: 7.Strategic Choices in CAR T for Myeloma: Balancing Efficacy, Safety, and BCMA vs. GPRC5D Options

Video content above is prompted by the following:

• Considering Robert's age and comorbidities, what factors influence your treatment decision for second-line therapy?
  • What other second-line options would you consider, and why? How do you approach the decision between CAR-T therapy and other novel agents in the second-line setting?
• Let's review the data supporting cilta-cel in the second-line setting?
  • What key findings from the CARTITUDE trials inform your decision to use cilta-cel in second-line treatment?
  • How do these results compare to other second-line options for multiple myeloma in this patient population?
• Discuss your experience using cilta-cel in the second-line setting:
  • What benefits have you observed in terms of efficacy and quality of life across different patient groups?
  • Are there any specific considerations or adaptations you make when treating patients with comorbidities like Robert's?